1 CNRS UMR 8542, Ecole Normale Supérieure, 46 rue d'Ulm, 75005 Paris,
France
2 Department of Neurochemistry, Max Planck Institute for Brain Research, D-60528
Frankfurt, Germany
* Author for correspondence (e-mail: prochian{at}wotan.ens.fr)
Accepted 29 January 2004
![]() |
SUMMARY |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Key words: APP, Subventricular zone, Neurogenesis, Proliferation
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In addition to its still elusive role as a membrane-bound protein, APP can
be cleaved to produce soluble derivatives with biological activity. In
non-pathological situations, APP is predominantly cleaved by the
-secretase within the ß-amyloid sequence, to release a soluble
form of APP, sAPP (see Fig.
3A). sAPP is normally present in brain tissues and circulates in
the cerebrospinal fluid (CSF) (Palmert et
al., 1989
). A number of in vitro studies have attempted to uncover
sAPP neuronal functions, showing that sAPP enhances synaptogenesis, neurite
outgrowth, cell survival and cell adhesion
(Mattson, 1997
). These
growth-promoting properties, together with its structural similarities with
cysteine-rich growth factors (Rossjohn et
al., 1999
), suggest that sAPP may function as a growth factor in
vivo. Interestingly, infusion of sAPP into the brain increases synaptic
density and improves memory retention
(Meziane et al., 1998
;
Roch et al., 1994
) and levels
of sAPP are decreased in the CSF of individuals with AD
(Lannfelt et al., 1995
;
Van Nostrand et al., 1992
).
Moreover, sAPP stimulates proliferation of neural stem cells isolated from the
embryonic brain (Hayashi et al.,
1994
; Ohsawa et al.,
1999
).
|
We show that the SVZ is a major binding site for sAPP in the adult brain and that sAPP binds EGF-responsive cells. In vitro, EGF stimulates sAPP secretion by NS cells and sAPP is required for full EGF mitogenic activity. In vivo, modulating levels of sAPP results in modifications of the number of EGF-responsive cells composing the SVZ transit amplifying compartment through regulation of their proliferation. This work therefore provides strong evidence for a function of sAPP in adult neurogenesis.
![]() |
Materials and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Immunostaining
For immunostaining on sections, the mice (Swiss, 2-month-old) were perfused
(4% paraformaldehyde), their brains were removed, postfixed overnight and
sectioned with a vibratome (frontal sections, 50 µm). Sections were blocked
in PBS, 10% fetal calf serum, 0.3% triton and incubated in primary antibodies
or sAPP-Fc, sAPLP1-Fc, sAPLP2-Fc diluted in the same buffer for 36 hours at
4°C under agitation. The Fc-tagged proteins were used at a concentration
of 10 µg/ml. Antibodies were rabbit anti-APP C-terminal extremity, rabbit
anti-EGFR (1:500, Santa-Cruz Biotechnology), mouse IgM anti-PSA-NCAM (1:1000,
gift from G. Rougon), rabbit anti-S100 (1:1000, DAKO), rabbit anti-APLP1
(1:2000, anti-CT11) and rabbit anti-APLP2 (1:2000, Dll2). Fluorescent
secondary antibodies were FITC or Cy3 donkey anti-species (1:1000, Jackson
Immunoresearch).
For whole-mount staining, the mice were perfused with 2% paraformaldehyde,
the lateral wall of the lateral ventricle (injected side) was dissected and
immunohistochemistry was performed as described
(Doetsch et al., 1999b).
Infusions in vivo
sAPP-Fc (200 µg/ml), sAPLP2-Fc (200 µg/ml), human IgG (200 µg/ml,
Sigma), batimastat (100 µM, Glaxo Smith Kline), APP oligonucleotides [20
µM, designed 10 to +10 around the mRNA initiation site and coupled
to penetratin (Derossi et al.,
1998)] or APLP2 oligonucleotides (20 µM, designed 3 to
+15 around the mRNA initiation site and coupled to penetratin) were diluted in
0.09% NaCl. At least six adult mice for each condition were infused
continuously for 3 days into the lateral ventricle (coordinates:
anterior/posterior, 0; lateral, 0.8 mm; dorsal, 2 mm, relative to bregma)
using micro-osmotic pumps (1 µl/hour, model 1003, Alzet). It is assumed
that the solution in the pump is diluted at least ten times upon infusion in
the CSF.
Ara-C (2%, Sigma) in vehicle (0.9% saline) or vehicle alone was infused
onto the surface of the brain of adult mice (coordinates: anterior/posterior,
0; lateral, 1.1 mm relative to bregma) for 6 days with micro-osmotic pumps
(Alzet, model 1007) as described (Doetsch
et al., 1999b).
Quantification of proliferation
For quantification of EGF-responsive cell proliferation, infused animals
(n=3 for each condition) were injected intraperitoneally with BrdU (1
mg in 100 µl) 1 hour before perfusion with 4% paraformaldehyde. Brains were
removed, postfixed for 2 hours and cryoprotected in 20% saccharose overnight.
They were frozen and 10 µm thick sections were cut using a cryostat.
Frontal sections (20 per brain) at different levels of the SVZ (between +1 mm
and 0mm anterior to bregma) were double-labeled for EGFR (sheep anti-human
EGFR, 1:100, Upstate Biotechnology) and BrdU (rat anti-BrdU, Accurate
chemical, 1:200), and mounted with DAPI-containing mounting medium. Clearly
identifiable EGFR immunopositive cells were scored individually for their BrdU
immunoreactivity under the 100x objective of a Leica fluorescence
microscope.
For quantification of BrdU-positive cells in whole-mount preparations, cells were counted on a predefined area corresponding to the anterior subventricular zone using a computerized Biocom analysis system.
Neurosphere culture and assays
NS were prepared, cultured in serum-free medium with EGF (20 ng/ml),
passaged and differentiated to assess their multipotentiality as described
(Doetsch et al., 1999a). All
experiments were performed on NS that had been passaged several times.
To stain sAPP-binding sites on NS cells, 8-day-old in vitro (DIV) NS were plated onto poly-L-ornithin (15 µg/ml) and laminin (10 µg/ml) coated chamber-slides (16 well Lab-Tek, Nunc) in medium without EGF for 4 hours. Cells were fixed in 4% paraformaldehyde for 15 minutes, rinsed in PBS and blocked in PBS with 10% fetal calf serum for 1 hour. They were incubated overnight at 4°C in sAPP-Fc diluted to 10 µg/ml in PBS with 10% fetal calf serum. The signal was developed as for sections. Cells were mounted with DAPI-containing vectashield mounting medium (Vector).
To measure sAPP secretion by NS, 8 DIV NS were centrifuged, resuspended in fresh medium and plated into 96-well plates (approximately 1000 NS per well in 50 µl medium). After 15 hours, NS were centrifuged and the medium and cellular pellet from each separate well were processed independently for immunoblotting using the 22C11 antibody (Chemicon). The signal was developed using the application Image Gauge.
To evaluate NS cell proliferation, cells from dissociated NS were plated onto poly-L-ornithin, laminin-coated chamber-slides (16-well Lab-Tek, 2000 cells per well) and grown in EGF-containing medium (2 ng/ml) for 4 days. Cells were rinsed three times in fresh medium and cultured for 15 hours in medium with EGF (2 ng/ml), BrdU (1 µM) and antibodies against sAPP (22C11, Chemicon; 6E10, Senetek) diluted to a concentration of 1.5 µg/ml. Cells were fixed, processed for BrdU immunocytochemistry (mouse anti-BrdU, DAKO, 1:50), mounted with DAPI-containing mounting medium and the percentage of BrdU-positive nuclei was calculated.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
sAPP participates in the EGF-induced proliferation of adult SVZ progenitors in vitro
The two likely cellular targets of infused sAPP are neuroblasts (Type A
cells) and EGF-responsive cells (Type C cells), which both express
sAPP-binding sites. We have focused the present study on the effect of sAPP on
EGF-responsive cells. These cells can be cultured and, in the presence of EGF,
they proliferate and form small aggregates called neurospheres (NS). We first
verified if NS cells can bind sAPP. Detection of sAPP-Fc on plated NS cells
showed that they do bind sAPP, with a punctuate staining pattern at the cell
surface (Fig. 2B). To determine
whether NS cells also secrete sAPP, we immunoblotted media conditioned by NS
cultured with 0, 2 or 20 ng/ml of EGF. EGF causes a concentration-dependent
increase in the release of sAPP (Fig.
2C, upper panel). By contrast, cellular APP remains approximately
constant at the three EGF concentrations
(Fig. 2C, lower panel). It is
noteworthy that a similar growth factor-induced sAPP release has been shown in
different cell lines (Schubert et al.,
1989; Slack et al.,
1997
).
|
The 22C11 antibody has been shown to induce intracellular signaling through
binding to membrane APP, thus mimicking the action of an unknown endogenous
ligand (Brouillet et al., 1999;
Okamoto et al., 1995
). We
therefore followed the proliferation of NS cells in the presence of a
different antibody (6 E10) that binds another region comprised between amino
acids 597 and 613 of the APP N terminus
(Fig. 2A). Addition of this
antibody also leads to a decrease in the percentage of BrdU-positive cells
(29±3%) and this decrease is also prevented by a pre-incubation of the
antibody with its epitope (57±2%)
(Fig. 2D, t-test
P<0.001). The similar decrease of proliferation provoked by two
antibodies recognizing two distinct epitopes suggests that they act by
sequestering the sAPP released into the medium upon EGF addition and not
through a ligand-like signaling activity. We also verified that the decrease
in BrdU incorporation does not reflect a cell survival effect by counting the
number of apoptotic TUNEL-positive cells. We found that the percentage of
apoptotic cells remained unchanged after the addition of either anti-APP
antibody (control, 7.2±1.1%; 22C11, 7.4±1.8%; 6 E10,
7.8±1.5%).
The effect of sAPP on NS cell differentiation was tested by adding sAPP-Fc or anti-APP antibodies in conditions that induce the differentiation of NS cells into neurons, astrocytes and oligodendrocytes. Compared with control conditions, the relative percentages of each differentiated cell types were found unaltered by these treatments (not shown), suggesting that sAPP does not play a role in NS differentiation in vitro.
Taken together, these results suggest that the EGF-induced proliferation of NS cells is partly dependent on the EGF-induced release of sAPP into the medium. However, sAPP is necessary but not sufficient as it does not induce cell division in EGF-free medium. Finally, the addition of exogenous sAPP-Fc (0.1 to 20 µg/ml) to EGF-containing medium did not lead to a further increase in NS cells proliferation (not shown), a finding that may be explained by a saturating effect of the EGF-induced secretion of endogenous APP. We thus decided to turn to the in vivo situation to test the effects of sAPP gain and loss of function on the proliferation of adult progenitors.
sAPP increases proliferation of EGF-responsive adult progenitors in vivo
To determine whether sAPP also acts on EGF-responsive SVZ cells in vivo, we
unilaterally infused sAPP-Fc (200 µg/ml) or human IgG (same concentration)
into the lateral ventricle for 3 days and prepared NS from the SVZ ipsilateral
to the side of the infusion. The number of NS growing from each SVZ reflects
the total number of NS precursors present in the SVZ at the time of dissection
(Morshead et al., 1994). The
average number of NS obtained from the SVZ of control mice infused with human
IgG was 1940±89. This number, and therefore the number of progenitors
present in vivo, increased up to 2444±49 after infusion of sAPP-Fc
(Fig. 3A, t-test
P<0.01).
These NS were tested for their ability of self-renewal and their
differentiation properties and showed no difference as compared to control NS
(not shown). Because NS precursors are mainly EGF-responsive Type C cells
(Doetsch et al., 2002), this
suggested an increase in the number of these progenitors. To assess whether
this increase reflected their enhanced proliferation, BrdU was injected, 1
hour before sacrifice, into animals that had been infused for 3 days and the
cells double-stained for BrdU and EGFR were counted. A larger fraction of
EGF-responsive cells were BrdU-positive in sAPP-Fc infused mice
(64.9±6%) compared with control mice infused with human IgG
(43±2%) (Fig. 3B,
t-test P<0.01). This suggests that sAPP positively
regulates the proliferation of EGF-responsive SVZ adult progenitors in
vivo.
Decreasing sAPP reduces the proliferation of EGF-responsive adult progenitors in vivo
The -secretase activity, which allows the production of sAPP from
APP, can be inhibited by hydroxamic acid-based zinc metalloprotease inhibitors
such as batimastat (Parvathy et al.,
1998
).
Therefore, to evaluate the effect of a reduction of sAPP concentration on EGF-responsive SVZ cells, we unilaterally infused batimastat (100 µM) into the lateral ventricle for 3 days and prepared NS from the SVZ, as above. The number of NS was reduced from 1856±36 in control mice to 626±34 after batimastat infusion (Fig. 3C, t-test P<0.001). Because batimastat probably inhibits the cleavage of several membrane proteins in addition to APP, we tested the specificity of the effect by co-infusing sAPP-Fc (200 µg/ml) and batimastat before preparing NS. As shown in Fig. 3C, sAPP addition fully reversed the effect of batimastat, restoring the number of NS back to control levels (1948±60). This strongly suggests that the reduction of SVZ progenitors upon batimastat infusion is a consequence of a decrease in the cleavage of APP, sAPP and not of another unknown factor.
As an independent means of assessing the effect of sAPP reduction, we
infused an antisense oligonucleotide (20 µM) directed against APP and
linked to penetratin for internalization
(Derossi et al., 1998). This
linkage catalyses an extremely efficient addressing of the oligonucleotide
into the cell cytoplasm and nucleus
(Allinquant et al., 1995
). It
allows the use of low concentrations of oligonucleotides, thus preventing
undesirable effects of the polyanionic nature of oligonucleotides.
Quantification of APP in the SVZ by immunoblot shows a 30% reduction in
antisense- as compared to sense-infused animals
(Fig. 3C). The number of NS
growing after infusion of sense oligonucleotides was 2167±18, whereas
infusion of antisense oligonucleotides led to a reduction to 1229±34
(Fig. 3C, t-test
P<0.01). This indicates that a reduced synthesis of APP leads to a
reduction in the number of EGF-responsive progenitors.
To evaluate if, as anticipated from the in vitro studies, this reduction of the pool of progenitors was a consequence of their reduced proliferation, we injected BrdU into infused animals and calculated the percentage of EGF-responsive cells labeled with BrdU, as above. A lesser fraction of EGF-responsive cells were BrdU-positive in antisense-infused (33.8±1.4%) compared with sense-infused mice (42.7±1.8%) (Fig. 3D, t-test P<0.01). Because antisense treatment reduces APP synthesis and thus both the transmembrane form and its released extracellular domain (sAPP), we tested whether sAPP could rescue this reduction of proliferation. This was indeed the case as the percentage of BrdU-positive EGFR immunoreactive cells was above control levels in animals co-infused with antisense and sAPP (54±2.2%) (Fig. 3D, t-test P<0.01). This suggests that the reduction of proliferation of SVZ progenitors upon antisense infusion results from a decrease in sAPP and confirms that a reduction of sAPP level leads to reduced proliferation of adult SVZ progenitors.
Taken together, these data strongly suggest that sAPP regulates the
proliferation of SVZ progenitors. However, as illustrated in
Fig. 1, sAPP-binding sites are
present in vivo both on Type C cells (EGFR-expressing progenitors) and Type A
cells (PSA-NCAM-expressing neuroblasts). To verify that sAPP directly acts on
type C cells and that sAPP-induced progenitor proliferation does not happen
through an indirect action on type A cells, we took advantage of the
well-defined system of SVZ regeneration after infusion of the antimitotic drug
cytosine-ß-D-arabinofuranoside (Ara-C)
(Doetsch et al., 1999b). In
this model, after elimination of all Type C and A cells by Ara-C, the SVZ
regenerates rapidly with a sequential reappearance of type C (2 days after
termination of Ara-C treatment) and A cells (4 days after treatment). This
system allows one to follow the response of type C cells in the absence of
neuroblasts. We thus infused antibodies directed against sAPP (6 E10, 200
µg/ml) or control IgG (same concentrations) during the first 3 days of
regeneration before the reappearance of type A cells. BrdU was injected 1 hour
before sacrifice to count the total number of proliferating cells on
whole-mount preparations of the anterior SVZ. The number of BrdU-positive
cells was significantly reduced in antibody-infused animals (557±78)
when compared with control animals (1235±45)
(Fig. 3E, t-test
P<0.01). This strongly suggests that a reduction of circulating
sAPP downregulates type C cell proliferation and that this reduction is a
direct effect of sAPP on type C cells.
sAPLP2 is functionally redundant with sAPP in the SVZ
This study points towards a role for sAPP in regulating the proliferation
of cells composing the SVZ transit amplifying compartment. APP is a member of
a larger gene family, including the two amyloid precursor-like proteins APLP1
and APLP2 (Slunt et al., 1994;
Wasco et al., 1992
). APLPs are
highly homologous to APP and can be processed in a similar way, leading to the
secretion of their ectodomains (sAPLP)
(Paliga et al., 1997
;
Slunt et al., 1994
). It is
thus possible that sAPLPs and sAPP have redundant functions in the SVZ.
As illustrated in the western blot of Fig. 4C, both APLP1 and APLP2 are expressed in the SVZ. However, when Fc-tagged sAPLPs were used to detect if binding sites are present on brain tissue sections, it was found that sAPLP2-Fc stained SVZ cells similarly to sAPP-Fc (Fig. 4B), whereas sAPLP1-Fc showed no detectable binding (Fig. 4A). We therefore assessed whether sAPLP2 could stimulate the proliferation of EGF-responsive cells by infusing sAPLP2-Fc in the lateral ventricle and counting the number of NS growing from the infused SVZ. The average number of NS obtained from control mice infused with human IgG was 1862±58 and increased up to 3050±50 upon sAPLP2-Fc infusion (Fig. 4D, t-test P<0.01). Conversely, infusion of a penetratin-linked antisense oligonucleotide directed to APLP2, which leads to a 30% decrease in APLP2 synthesis (Fig. 4D), was paralleled by a significant decrease in the number of NS (1276±104). This decrease was not observed with a control sense oligonucleotide (1972±68) (Fig. 4D, t-test P<0.01).
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Specificity of sAPP binding and activity
The binding of sAPP-Fc on both Type A and Type C cells clearly indicates
that the protein probably has multiple sites of action and may not only
influence the rate of division of Type C cells but also the division and
migration of Type A cells. Although we do not preclude an effect on Type A
cells, the experiments on Ara-C-treated animals demonstrate that the effect on
Type C cell proliferation is not an indirect consequence of an effect on type
A cells. This justifies the focus put, in this study, on the role of sAPP in
Type C cell growth regulation.
Another aspect of specificity is the lack of binding of sAPP-Fc in the
dentate gyrus, a second site of neurogenesis in the adult CNS. The absence of
sAPP-Fc binding is not due to a lack of penetration of sAPP-Fc because a
similar reagent, L1-Fc, binds both SVZ and hippocampal cells. This means that,
at least in the adult, the number of sites or their affinity is lower than in
the SVZ. This correlates with an absence of biological activity of sAPP-Fc, as
monitored by the number of BrdU-labeled cells in the dentate gyrus after
infusion of sAPP-Fc [on 10 representative sections, this number was
51±5 in sAPP-Fc infused animals and 54±3 in control animals
(mean±s.e.m., n=3)]. This finding is apparently at odds with
some in vitro studies on hippocampal cells showing that sAPP or smaller
peptides derived from sAPP have a trophic action or influence neuronal
excitability (Mattson, 1997).
Some of these studies provide evidence for an underlying signal transduction
pathway suggesting the existence of a receptor for sAPP. However, most of the
above-mentioned studies have been performed on embryonic cells or on cell
lines and not on adult brain or NS cells derived from adult brain.
The absence of sAPP-binding sites in the dentate gyrus of the hippocampus
and its ineffectiveness at promoting proliferation in this region also
suggests that, in the adult, its role in neurogenesis could be limited to the
SVZ. This is consistent with the fact that dentate gyrus neurogenesis is
regulated differently from SVZ neurogenesis. In particular, the dentate gyrus
progenitors are more restricted in their potentiality than SVZ progenitors and
cannot be cultured as NS (Seaberg and van
der Kooy, 2002). In line with this, an EGF-responsive transit
amplifying compartment similar to the SVZ type C cells, shown here to be
regulated by sAPP, is missing in the dentate gyrus
(Seri et al., 2001
).
A function for sAPP in regulating the proliferation of different cell types
has been proposed in previous studies performed on cell lines
(Hayashi et al., 1994;
Hoffmann et al., 2000
;
Ohsawa et al., 1999
;
Pietrzik et al., 1998
;
Saitoh et al., 1989
).
Interestingly, sAPP has been described as an autocrine regulator of epidermal
basal cell proliferation (Hoffmann et al.,
2000
), which, similar to SVZ progenitor proliferation, is under
the control of TGF
, a member of the EGF family that acts though the EGF
receptor. Cultured keratinocytes also exhibit sAPP-binding sites similar to
the ones we observed in the SVZ or on cultured NS. In line with the results
presented here, sAPP was described to stimulate proliferation of embryonic
neural stem cells (Hayashi et al.,
1994
; Ohsawa et al.,
1999
). Accordingly, we could detect sAPP-binding sites not only on
adult NS cells and SVZ but also on NS cells cultured from the embryonic brain
(Fig. 5). Consequently, whereas
this study is limited to adult neurogenesis, it is possible that sAPP also
triggers progenitor proliferation at early developmental stages. This
possibility is supported by the reduced brain volume of mice deleted for APP
(Zheng et al., 1995
) and by a
study on transgenic mice overexpressing a mutant form of APP
(Bondolfi et al., 2002
),
revealing that these mice have 10-15% more cortical neurons than wild-type
control mice. This, in view of the present results, could be a consequence of
an increased neurogenesis consecutive to an increase in sAPP
concentration.
|
Also in favor of a direct role for sAPP as opposed to transmembrane APP, is the effect of inhibition of sAPP formation through batimastat infusion, which is fully reversed by the infusion of sAPP. In addition, antisense infusions are extremely demonstrative as the decrease in transmembrane APP is compensated by sAPP in the absence of a restoration of the normal concentrations of the transmembrane form. These data, together with the specificity of action of sAPP on the SVZ, which presents the highest concentration of sAPP-binding sites, support the idea that it is sAPP that triggers Type C cell proliferation and that, as far as this activity is concerned, transmembrane APP acts as a precursor. This, indeed, does not preclude other functions associated with this transmembrane form.
sAPP and sAPLP2 as EGF/TGF co-factors
The signaling pathway triggered by sAPP was not investigated here. It is
important to note that, in the model that we propose, the activity of EGF
requires that sAPP be present in the medium. sAPP is necessary, but not
sufficient for EGF activity (it cannot replace EGF) and thus, in this model,
acts as an EGF co-factor for Type C cell proliferation. It would be of great
interest, in the future, to identify which pathways are co-regulated by the
two molecules. To this extent, it is interesting that two studies have
reported a stimulation of MAP kinase activity by sAPP
(Greenberg et al., 1994;
Pietrzik et al., 1998
). It is
also striking that, in vitro, the addition of sAPP in the presence of EGF does
not further enhance NS proliferation. This situation differs from that
observed in vivo, where the infusion of sAPP has a growth-promoting effect.
This difference between the in vitro and in vivo situations might be due to
the low levels of sAPP at the vicinity of their target cells, possibly owing
to its fast clearance in the CSF. If so, sAPP would be a limiting factor for
Type C cell proliferation in the adult SVZ.
We show that sAPLP2 also binds SVZ cells and acts similarly to sAPP on
EGF-responsive progenitors, demonstrating a physiological function for sAPLP2.
These results confirm the functional redundancy between APP and APLP2,
postulated on the basis on their high degree of homology (up to 72% identical
in the cysteine-rich regions of their ectodomains)
(Wasco et al., 1992) and from
the lethal phenotype of the double knockout mice
(Heber et al., 2000
;
von Koch et al., 1997
) as
opposed to minor phenotypes of viable single knockouts
(Li et al., 1996
;
Zheng et al., 1995
). This
redundancy associated with the structural similarities between the two
proteins and the fact that sAPP is a limiting factor, as proposed above,
provides a rational for the fact that the two proteins have the same effects
on Type-C cell proliferation and suggests that they act on the same receptors.
The absence of compensation between the two molecules in the adult
loss-of-function experiments is also in agreement with their limiting
concentrations. This is not contradictory with the compensation observed in
the genetic deletions as gene deletion in the embryo sets up permanent
compensation phenomena not observed in the acute adult treatments used in this
study.
sAPP and AD
The present findings might have implications for the understanding of AD.
The extent and significance of adult neurogenesis in the human brain is a
matter of controversy. However, human and rodent SVZ cells express similar
markers, including the EGFR (Weickert et
al., 2000). A subset of human SVZ cells have been shown to divide
(Eriksson et al., 1998
) and
the human SVZ is neurogenic in vitro
(Kirschenbaum et al., 1994
).
This supports the view that SVZ neurogenesis is similarly regulated in all
mammals. In the light of the reduction in sAPP concentrations in brains from
individuals with AD (Lannfelt et al.,
1995
; Van Nostrand et al.,
1992
), the present data that link sAPP levels and the number of
SVZ progenitors, suggest that a deficit in neurogenesis could play a role in
some aspects of AD pathogenesis. Interestingly, individuals with AD show very
early odor discrimination defects (Nordin
and Murphy, 1998
) as do mutant mice with reduced SVZ neurogenesis
(Gheusi et al., 2000
). Even
though impaired olfaction in AD could be a consequence of cortical
neurodegeneration, reduced olfactory bulb neurogenesis could participate in
this phenomenon. Similarly, it is interesting that the primate SVZ gives rise
to neurons destined to the amygdala and pyriform cortex
(Bernier et al., 2002
), two
regions important for emotions and memory and atrophied in AD
(Callen et al., 2001
). Added to
the implication of adult neurogenesis in learning and memory
(Scharff, 2000
), this
observation suggests that some cognitive impairments in AD might result from a
defect in SVZ neurogenesis.
![]() |
ACKNOWLEDGMENTS |
---|
![]() |
REFERENCES |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Allinquant, B., Hantraye, P., Mailleux, P., Moya, K., Bouillot, C. and Prochiantz, A. (1995). Downregulation of amyloid precursor protein inhibits neurite outgrowth in vitro. J. Cell Biol. 128,919 -927.[Abstract]
Alvarez-Buylla, A. and Garcia-Verdugo, J. M. (2002). Neurogenesis in adult subventricular zone. J. Neurosci. 22,629 -634.[CrossRef][Medline]
Bernier, P. J., Bedard, A., Vinet, J., Levesque, M. and Parent,
A. (2002). Newly generated neurons in the amygdala and
adjoining cortex of adult primates. Proc. Natl. Acad. Sci.
USA 99,11464
-11469.
Bondolfi, L., Calhoun, M., Ermini, F., Kuhn, H. G., Wiederhold,
K. H., Walker, L., Staufenbiel, M. and Jucker, M. (2002).
Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid
precursor protein transgenic mice. J. Neurosci.
22,515
-522.
Brouillet, E., Trembleau, A., Galanaud, D., Volovitch, M.,
Bouillot, C., Valenza, C., Prochiantz, A. and Allinquant, B.
(1999). The amyloid precursor protein interacts with Go
heterotrimeric protein within a cell compartment specialized in signal
transduction. J. Neurosci.
19,1717
-1727.
Callen, D. J., Black, S. E., Gao, F., Caldwell, C. B. and
Szalai, J. P. (2001). Beyond the hippocampus: MRI volumetry
confirms widespread limbic atrophy in AD. Neurology
57,1669
-1674.
Craig, C. G., Tropepe, V., Morshead, C. M., Reynolds, B. A., Weiss, S. and van der Kooy, D. (1996). In vivo growth factor expansion of endogenous subependymal neural precursor cell populations in the adult mouse brain. J. Neurosci. 16,2649 -2658.[Abstract]
De Strooper, B. and Annaert, W. (2000).
Proteolytic processing and cell biological functions of the amyloid precursor
protein. J. Cell Sci.
113,1857
-1870.
Derossi, D., Chassaing, G. and Prochiantz, A. (1998). Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol. 8, 84-87.[CrossRef][Medline]
Doetsch, F., Caille, I., Lim, D. A., Garcia-Verdugo, J. M. and Alvarez-Buylla, A. (1999a). Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97,703 -716.[Medline]
Doetsch, F., Garcia-Verdugo, J. M. and Alvarez-Buylla, A.
(1999b). Regeneration of a germinal layer in the adult mammalian
brain. Proc. Natl. Acad. Sci. USA
96,11619
-11624.
Doetsch, F., Petreanu, L., Caille, I., Garcia-Verdugo, J. M. and Alvarez-Buylla, A. (2002). EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron 36,1021 -1034.[Medline]
Doherty, P., Williams, E. and Walsh, F. S. (1995). A soluble chimeric form of the L1 glycoprotein stimulates neurite outgrowth. Neuron 14, 57-66.[Medline]
Eriksson, P. S., Perfilieva, E., Bjork-Eriksson, T., Alborn, A. M., Nordborg, C., Peterson, D. A. and Gage, F. H. (1998). Neurogenesis in the adult human hippocampus. Nat. Med. 4,1313 -1317.[CrossRef][Medline]
Gheusi, G., Cremer, H., McLean, H., Chazal, G., Vincent, J. D.
and Lledo, P. M. (2000). Importance of newly generated
neurons in the adult olfactory bulb for odor discrimination. Proc.
Natl. Acad. Sci. USA 97,1823
-1828.
Greenberg, S. M., Koo, E. H., Selkoe, D. J., Qiu, W. Q. and Kosik, K. S. (1994). Secreted beta-amyloid precursor protein stimulates mitogen-activated protein kinase and enhances tau phosphorylation. Proc. Natl. Acad. Sci. USA 91,7104 -7108.[Abstract]
Hayashi, Y., Kashiwagi, K., Ohta, J., Nakajima, M., Kawashima, T. and Yoshikawa, K. (1994). Alzheimer amyloid protein precursor enhances proliferation of neural stem cells from fetal rat brain. Biochem. Biophys. Res. Commun. 205,936 -943.[CrossRef][Medline]
Heber, S., Herms, J., Gajic, V., Hainfellner, J., Aguzzi, A.,
Rulicke, T., von Kretzschmar, H., von Koch, C., Sisodia, S., Tremml, P. et
al. (2000). Mice with combined gene knock-outs reveal
essential and partially redundant functions of amyloid precursor protein
family members. J. Neurosci.
20,7951
-7963.
Hoffmann, J., Pietrzik, C. U., Kummer, M. P., Twiesselmann, C.,
Bauer, C. and Herzog, V. (1999). Binding and selective
detection of the secretory N-terminal domain of the alzheimer amyloid
precursor protein on cell surfaces. J. Histochem.
Cytochem. 47,373
-382.
Hoffmann, J., Twiesselmann, C., Kummer, M. P., Romagnoli, P. and Herzog, V. (2000). A possible role for the Alzheimer amyloid precursor protein in the regulation of epidermal basal cell proliferation. Eur. J. Cell Biol. 79,905 -914.[Medline]
Hung, A. Y., Koo, E. H., Haass, C. and Selkoe, D. J. (1992). Increased expression of beta-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage. Proc. Natl. Acad. Sci. USA 89,9439 -9443.[Abstract]
Kempermann, G. (2002). Why new neurons? Possible functions for adult hippocampal neurogenesis. J. Neurosci. 22,635 -638.[CrossRef][Medline]
Kirschenbaum, B., Nedergaard, M., Preuss, A., Barami, K., Fraser, R. A. and Goldman, S. A. (1994). In vitro neuronal production and differentiation by precursor cells derived from the adult human forebrain. Cereb. Cortex 4, 576-589.[Abstract]
Kuhn, H. G., Winkler, J., Kempermann, G., Thal, L. J. and Gage,
F. H. (1997). Epidermal growth factor and fibroblast growth
factor-2 have different effects on neural progenitors in the adult rat brain.
J. Neurosci. 17,5820
-5829.
Lannfelt, L., Basun, H., Wahlund, L. O., Rowe, B. A. and Wagner, S. L. (1995). Decreased alpha-secretase-cleaved amyloid precursor protein as a diagnostic marker for Alzheimer's disease. Nat. Med. 1,829 -832.[Medline]
Li, Z. W., Stark, G., Gotz, J., Rulicke, T., Gschwind, M.,
Huber, G., Muller, U. and Weissmann, C. (1996). Generation of
mice with a 200-kb amyloid precursor protein gene deletion by Cre
recombinase-mediated site-specific recombination in embryonic stem cells.
Proc. Natl. Acad. Sci. USA
93,6158
-6162.
Magara, F., Muller, U., Li, Z. W., Lipp, H. P., Weissmann, C.,
Stagljar, M. and Wolfer, D. P. (1999). Genetic background
changes the pattern of forebrain commissure defects in transgenic mice
underexpressing the beta-amyloid-precursor protein. Proc. Natl.
Acad. Sci. USA 96,4656
-4661.
Mattson, M. P. (1997). Cellular actions of
beta-amyloid precursor protein and its soluble and fibrillogenic derivatives.
Physiol. Rev. 77,1081
-1132.
Meziane, H., Dodart, J. C., Mathis, C., Little, S., Clemens, J.,
Paul, S. M. and Ungerer, A. (1998). Memory-enhancing effects
of secreted forms of the beta-amyloid precursor protein in normal and amnestic
mice. Proc. Natl. Acad. Sci. USA
95,12683
-12688.
Morshead, C. M., Reynolds, B. A., Craig, C. G., McBurney, M. W., Staines, W. A., Morassutti, D., Weiss, S. and van der Kooy, D. (1994). Neural stem cells in the adult mammalian forebrain: a relatively quiescent subpopulation of subependymal cells. Neuron 13,1071 -1082.[Medline]
Nordin, S. and Murphy, C. (1998). Odor memory
in normal aging and Alzheimer's disease. Ann. New York Acad.
Sci. 855,686
-693.
Ohsawa, I., Takamura, C., Morimoto, T., Ishiguro, M. and Kohsaka, S. (1999). Amino-terminal region of secreted form of amyloid precursor protein stimulates proliferation of neural stem cells. Eur. J. Neurosci. 11,1907 -1913.[CrossRef][Medline]
Okamoto, T., Takeda, S., Murayama, Y., Ogata, E. and Nishimoto,
I. (1995). Ligand-dependent G protein coupling function of
amyloid transmembrane precursor. J. Biol. Chem.
270,4205
-4208.
Paliga, K., Peraus, G., Kreger, S., Durrwang, U., Hesse, L., Multhaup, G., Masters, C. L., Beyreuther, K. and Weidemann, A. (1997). Human amyloid precursor-like protein 1cDNA cloning, ectopic expression in COS-7 cells and identification of soluble forms in the cerebrospinal fluid. Eur. J. Biochem. 250,354 -363.[Abstract]
Palmert, M. R., Podlisny, M. B., Witker, D. S., Oltersdorf, T., Younkin, L. H., Selkoe, D. J. and Younkin, S. G. (1989). The beta-amyloid protein precursor of Alzheimer disease has soluble derivatives found in human brain and cerebrospinal fluid. Proc. Natl. Acad. Sci. USA 86,6338 -6342.[Abstract]
Parvathy, S., Hussain, I., Karran, E. H., Turner, A. J. and Hooper, N. M. (1998). Alzheimer's amyloid precursor protein alpha-secretase is inhibited by hydroxamic acid-based zinc metalloprotease inhibitors: similarities to the angiotensin converting enzyme secretase. Biochemistry 37,1680 -1685.[CrossRef][Medline]
Pietrzik, C. U., Hoffmann, J., Stober, K., Chen, C. Y., Bauer,
C., Otero, D. A., Roch, J. M. and Herzog, V. (1998). From
differentiation to proliferation: the secretory amyloid precursor protein as a
local mediator of growth in thyroid epithelial cells. Proc. Natl.
Acad. Sci. USA 95,1770
-1775.
Reynolds, B. A. and Weiss, S. (1992). Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 255,1707 -1710.[Medline]
Roch, J. M., Masliah, E., Roch-Levecq, A. C., Sundsmo, M. P., Otero, D. A., Veinbergs, I. and Saitoh, T. (1994). Increase of synaptic density and memory retention by a peptide representing the trophic domain of the amyloid beta/A4 protein precursor. Proc. Natl. Acad. Sci. USA 91,7450 -7454.[Abstract]
Rossjohn, J., Cappai, R., Feil, S. C., Henry, A., McKinstry, W. J., Galatis, D., Hesse, L., Multhaup, G., Beyreuther, K., Masters, C. L. et al. (1999). Crystal structure of the N-terminal, growth factor-like domain of Alzheimer amyloid precursor protein. Nat. Struct. Biol. 6,327 -331.[CrossRef][Medline]
Saitoh, T., Sundsmo, M., Roch, J. M., Kimura, N., Cole, G., Schubert, D., Oltersdorf, T. and Schenk, D. B. (1989). Secreted form of amyloid beta protein precursor is involved in the growth regulation of fibroblasts. Cell 58,615 -622.[Medline]
Salbaum, J. M. and Ruddle, F. H. (1994). Embryonic expression pattern of amyloid protein precursor suggests a role in differentiation of specific subsets of neurons. J. Exp. Zool. 269,116 -127.[Medline]
Scharff, C. (2000). Chasing fate and function of new neurons in adult brains. Curr. Opin. Neurobiol. 10,774 -783.[CrossRef][Medline]
Schubert, D., Jin, L. W., Saitoh, T. and Cole, G. (1989). The regulation of amyloid beta protein precursor secretion and its modulatory role in cell adhesion. Neuron 3,689 -694.[Medline]
Seaberg, R. M. and van der Kooy, D. (2002).
Adult rodent neurogenic regions: the ventricular subependyma contains neural
stem cells, but the dentate gyrus contains restricted progenitors.
J. Neurosci. 22,1784
-1793.
Seri, B., Garcia-Verdugo, J. M., McEwen, B. S. and
Alvarez-Buylla, A. (2001). Astrocytes give rise to new
neurons in the adult mammalian hippocampus. J.
Neurosci. 21,7153
-7160.
Slack, B. E., Breu, J., Muchnicki, L. and Wurtman, R. J. (1997). Rapid stimulation of amyloid precursor protein release by epidermal growth factor: role of protein kinase C. Biochem. J. 327,245 -249.[Medline]
Slunt, H. H., Thinakaran, G., von Koch, C., Lo, A. C., Tanzi, R.
E. and Sisodia, S. S. (1994). Expression of a ubiquitous,
cross-reactive homologue of the mouse beta-amyloid precursor protein (APP).
J. Biol. Chem. 269,2637
-2644.
Small, D. H., Mok, S. S. and Bornstein, J. C. (2001). Alzheimer's disease and Abeta toxicity: from top to bottom. Nat. Rev. Neurosci. 2, 595-598.[CrossRef][Medline]
Tropepe, V., Craig, C. G., Morshead, C. M. and van der Kooy,
D. (1997). Transforming growth factor-alpha null and
senescent mice show decreased neural progenitor cell proliferation in the
forebrain subependyma. J. Neurosci.
17,7850
-7859.
Van Nostrand, W. E., Wagner, S. L., Shankle, W. R., Farrow, J. S., Dick, M., Rozemuller, J. M., Kuiper, M. A., Wolters, E. C., Zimmerman, J., Cotman, C. W. et al. (1992). Decreased levels of soluble amyloid beta-protein precursor in cerebrospinal fluid of live Alzheimer disease patients. Proc. Natl. Acad. Sci. USA 89,2551 -2555.[Abstract]
von Koch, C. S., Zheng, H., Chen, H., Trumbauer, M., Thinakaran, G., van der Ploeg, L. H., Price, D. L. and Sisodia, S. S. (1997). Generation of APLP2 KO mice and early postnatal lethality in APLP2/APP double KO mice. Neurobiol. Aging 18,661 -669.[CrossRef][Medline]
Wasco, W., Bupp, K., Magendantz, M., Gusella, J. F., Tanzi, R. E. and Solomon, F. (1992). Identification of a mouse brain cDNA that encodes a protein related to the Alzheimer disease-associated amyloid beta protein precursor. Proc. Natl. Acad. Sci. USA 89,10758 -10762.[Abstract]
Weickert, C. S., Webster, M. J., Colvin, S. M., Herman, M. M., Hyde, T. M., Weinberger, D. R. and Kleinman, J. E. (2000). Localization of epidermal growth factor receptors and putative neuroblasts in human subependymal zone. J. Comp. Neurol. 423,359 -372.[CrossRef][Medline]
Zheng, H., Jiang, M., Trumbauer, M. E., Sirinathsinghji, D. J., Hopkins, R., Smith, D. W., Heavens, R. P., Dawson, G. R., Boyce, S., Conner, M. W. et al. (1995). ß-Amyloid precursor protein-deficient mice show reactive gliosis and decreased locomotor activity. Cell 81,525 -531.[Medline]